CN Stock MarketDetailed Quotes
002932 Wuhan Easy Diagnosis Biomedicine
- 19.09
- -0.17-0.88%
Market Closed Nov 8 15:00 CST
4.44BMarket Cap424.22P/E (TTM)
19.63High19.02Low49.74KlotVolume19.50Open19.26Pre Close95.80MTurnover3.19%Turnover Ratio59.29P/E (Static)232.52MShares25.0552wk High0.75P/B2.98BFloat Cap14.6652wk Low21.19Limit Up156.09MShs Float59.63Historical High17.33Limit Down3.17%Amplitude1.33Historical Low0.15Dividend TTM19.26Avg Price31.21KlotAsk0.79%Div YieldTTM100Lot Size17.16KlotBid
Wuhan Easy Diagnosis Biomedicine Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -63.95%225.62M | -71.30%154.27M | -83.63%60.96M | -92.88%749.54M | -91.62%625.93M | -89.77%537.56M | -85.03%372.4M | 272.12%10.53B | 285.38%7.47B | 360.27%5.25B |
| Operating revenue | -63.95%225.62M | -71.30%154.27M | -83.63%60.96M | -92.88%749.54M | -91.62%625.93M | -89.77%537.56M | -85.03%372.4M | 272.12%10.53B | 285.38%7.47B | 360.27%5.25B |
| Other operating revenue | ---- | --0 | ---- | --45.47K | ---- | --0 | ---- | --0 | ---- | --0 |
| Total operating cost | -42.99%319.89M | -53.20%212.17M | -65.90%104.19M | -83.99%720.15M | -79.34%561.15M | -75.47%453.35M | -59.61%305.5M | 301.42%4.5B | 285.64%2.72B | 329.94%1.85B |
| Operating cost | -66.40%108.76M | -75.43%68.78M | -82.51%36.41M | -90.18%342.7M | -85.91%323.72M | -82.69%279.97M | -67.92%208.22M | 393.78%3.49B | 395.32%2.3B | 499.38%1.62B |
| Operating tax surcharges | -62.41%992.15K | -69.33%703.19K | -82.98%305.6K | -96.24%2.25M | -93.71%2.64M | -92.69%2.29M | -84.88%1.8M | 366.92%59.79M | 360.30%41.98M | 451.13%31.36M |
| Operating expense | -31.89%78.66M | -33.09%54.93M | -47.61%24.08M | -74.28%115.95M | -38.92%115.48M | -34.73%82.1M | -7.09%45.96M | 128.05%450.77M | 64.88%189.05M | 62.31%125.78M |
| Administration expense | -33.64%51.98M | -28.34%37.49M | -33.02%18.84M | -20.67%112.64M | 26.87%78.33M | 37.23%52.31M | 47.18%28.13M | 86.95%141.98M | 42.22%61.74M | 29.79%38.12M |
| Financial expense | 89.73%-6.74M | 85.95%-4.95M | 77.71%-2.63M | 114.87%5.19M | -115.39%-65.66M | -63.32%-35.26M | -505.52%-11.79M | -494.15%-34.94M | -435.73%-30.48M | -1,082.02%-21.59M |
| -Interest expense (Financial expense) | -59.94%470.92K | ---- | ---- | 206.73%10.5M | -38.55%1.18M | 84.58%2.46M | ---- | 61.85%3.42M | 20.70%1.91M | -8.64%1.33M |
| -Interest Income (Financial expense) | 88.48%-8.21M | 85.77%-5.18M | ---- | 75.26%-4.39M | -508.99%-71.2M | -351.55%-36.36M | ---- | -51.70%-17.73M | -44.07%-11.69M | -48.34%-8.05M |
| Research and development | -19.12%86.24M | -23.23%55.22M | -18.09%27.18M | -63.59%141.42M | -31.34%106.63M | 26.41%71.93M | 15.22%33.18M | 192.56%388.36M | 97.29%155.31M | 15.58%56.91M |
| Credit Impairment Loss | -62.61%26.85M | -95.67%1.9M | -352.58%-6.88M | 78.40%-79.95M | 199.34%71.82M | 173.43%43.87M | 107.08%2.72M | -1,635.03%-370.09M | -307.06%-72.3M | -476.05%-59.74M |
| Asset Impairment Loss | --0 | --0 | ---- | 100.74%4.75M | --36.33M | ---- | ---- | ---646.67M | ---- | ---- |
| Other net revenue | 14.23%176.56M | 48.07%128.01M | 151.33%77.6M | 112.15%115.8M | 413.32%154.57M | 288.91%86.45M | 190.69%30.88M | -8,039.46%-953.31M | -222.06%-49.33M | -368.99%-45.76M |
| Fair value change income | --637.06K | --637.06K | ---- | 66.25%4.59M | --0 | ---- | ---- | --2.76M | ---- | ---- |
| Invest income | 164.45%78.46M | 87.40%54.86M | 20.82%26.86M | 243.25%120.55M | 87.02%29.67M | 292.16%29.28M | 402.51%22.23M | 5,116.17%35.12M | 869.73%15.86M | 7,148.59%7.47M |
| -Including: Investment income associates | 61.82%-902.26K | 61.82%-902.26K | ---- | -31.27%-6.73M | ---2.36M | -637.28%-2.36M | ---- | 11.17%-5.13M | ---- | 89.14%-320.55K |
| Asset deal income | 119.91%82.28K | 215.49%310.79K | ---36.01K | 3,062.38%307.82K | ---413.2K | ---269.11K | ---- | --9.73K | ---- | ---- |
| Other revenue | 310.97%70.53M | 417.83%70.3M | 873.67%57.66M | 156.47%65.56M | 141.64%17.16M | 108.53%13.57M | 38,569.24%5.92M | 185.75%25.56M | 779.25%7.1M | 1,177.73%6.51M |
| Operating profit | -62.49%82.28M | -58.92%70.11M | -64.85%34.37M | -97.14%145.19M | -95.34%219.35M | -94.92%170.66M | -94.24%97.78M | 199.20%5.08B | 286.03%4.71B | 378.72%3.36B |
| Add:Non operating Income | -24.28%338.53K | -19.77%177.07K | 136.34%125.22K | 419.64%877.52K | 157.28%447.09K | 35.78%220.71K | 2,196.92%52.98K | 992.59%168.87K | --173.78K | --162.55K |
| Less:Non operating expense | -18.88%4.54M | -38.97%2.57M | -80.57%375.62K | 71.52%6.18M | 134.63%5.6M | 113.31%4.21M | 1,036,291.40%1.93M | 10.15%3.6M | -26.68%2.39M | 608.31%1.97M |
| Total profit | -63.55%78.07M | -59.37%67.72M | -64.42%34.12M | -97.24%139.89M | -95.45%214.19M | -95.04%166.67M | -94.35%95.9M | 199.57%5.08B | 286.88%4.7B | 378.65%3.36B |
| Less:Income tax cost | -50.17%15.71M | -47.53%12.94M | -58.36%6.01M | -89.84%70.67M | -95.60%31.53M | -95.28%24.67M | -94.60%14.44M | 180.73%695.84M | 296.31%716.58M | 388.79%522.71M |
| Net profit | -65.86%62.36M | -61.43%54.77M | -65.49%28.11M | -98.42%69.22M | -95.42%182.66M | -94.99%142M | -94.30%81.46M | 202.80%4.38B | 285.24%3.99B | 376.82%2.84B |
| Net profit from continuing operation | -65.86%62.36M | -61.43%54.77M | -65.49%28.11M | -98.42%69.22M | -95.42%182.66M | -94.99%142M | -94.30%81.46M | 202.80%4.38B | 285.24%3.99B | 376.82%2.84B |
| Less:Minority Profit | -149.71%-18.57M | -135.31%-10.39M | -165.68%-3.94M | -103.32%-5.71M | -74.74%37.36M | -60.64%29.43M | -85.15%6.01M | 414.17%172.06M | 404.35%147.92M | 397.36%74.76M |
| Net profit of parent company owners | -44.30%80.94M | -42.12%65.16M | -57.52%32.05M | -98.22%74.93M | -96.21%145.3M | -95.92%112.57M | -94.57%75.45M | 197.79%4.21B | 281.76%3.84B | 376.29%2.76B |
| Earning per share | ||||||||||
| Basic earning per share | -44.44%0.35 | -42.86%0.28 | -71.43%0.14 | -98.21%0.33 | -96.26%0.63 | -95.94%0.49 | -94.60%0.49 | 85.53%18.46 | 134.73%16.83 | 191.55%12.07 |
| Diluted earning per share | -44.44%0.35 | -41.67%0.28 | -70.83%0.14 | -98.20%0.33 | -96.20%0.63 | -95.97%0.48 | -94.67%0.48 | 83.84%18.31 | 133.85%16.58 | 195.78%11.92 |
| Other composite income | 3.72M | |||||||||
| Other composite income of parent company owners | ---- | ---- | ---- | ---- | ---- | --3.72M | ---- | ---- | ---- | ---- |
| Total composite income | -65.86%62.36M | -62.41%54.77M | -65.49%28.11M | -98.42%69.22M | -95.42%182.66M | -94.86%145.72M | -94.30%81.46M | 202.80%4.38B | 285.24%3.99B | 376.82%2.84B |
| Total composite income of parent company owners | -44.30%80.94M | -43.97%65.16M | -57.52%32.05M | -98.22%74.93M | -96.21%145.3M | -95.79%116.29M | -94.57%75.45M | 197.79%4.21B | 281.76%3.84B | 376.29%2.76B |
| Total composite income of minority owners | -149.71%-18.57M | -135.31%-10.39M | -165.68%-3.94M | -103.32%-5.71M | -74.74%37.36M | -60.64%29.43M | -85.15%6.01M | 414.17%172.06M | 404.35%147.92M | 397.36%74.76M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data